Categories Earnings, Health Care

Earnings preview: Medical devices to drive Abbott Q1 results

Abbott Laboratories (NYSE: ABT) is scheduled to report its earnings results for the first quarter of 2019 on Wednesday before the market opens. The results could be benefited by the segments Medical Devices, Established Pharmaceuticals, and Diagnostics as well as Nutrition that are likely to yield a greater return for the quarter.

The company has been consistently investing in its research and development for bringing out a new product pipeline that could achieve high productive and strong growth trends for the first quarter. The diagnostic instruments Alinity and infectious disease testing could drive Diagnostics sales higher. The cardiac mapping, ablation catheters, Structural Heart and Diabetes Care could drive sales of Medical Devices higher.

Abbott diagnostics center
Image Courtesy: Abbott / Facebook page

Analysts expect Abbott’s earnings to increase by 3.40% to $0.61 per share and revenue to rise by 1.10% to $7.47 billion for the first quarter. In comparison, during the previous year quarter, the company reported a profit of $0.59 per share on revenue of $7.39 billion.

Investors remained confused whether Abbott will beat the analysts’ expectations as the company’s history suggested it exceeded two times in the last four quarters while coming in line for the balance.

For the fourth quarter, the company swung to a profit from a loss last year, driven by a decline in tax expense. Worldwide sales increased 2.3% on a reported basis and 6.4% on an organic basis, helped by higher sales from Medical Devices and Diagnostics businesses.

For the first quarter, Abbott had expected earnings from continuing operations in the range of $0.25 to $0.27 per share and adjusted earnings to be $0.60 to $0.62 per share range. For the full year 2019, the company had predicted organic sales growth of 6.5% to 7.5% and earnings from continuing operations in the range of $1.80 to $1.90 per share. Adjusted earnings from continuing operations were anticipated to be in the range of $3.15 to $3.25 per share for the full year.

Shares of Abbott opened higher on Tuesday and is trading in the green territory. The stock has risen over 32% in the past year and over 10% in the past three months.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top